Pfizer will invest €90.5 million in Valneva
Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
20-Jun-2022 -
Valneva SE and Pfizer Inc. announced that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15. As previously announced on April 26, 2022, Pfizer plans to initiate the Phase 3 study ...
investments
Lyme disease
Pfizer
+2